- Home
- WYY vs ANL Comparison
WYY vs ANL Comparison
Compare WYY & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WYY | ANL |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 52.0M |
| IPO Year | 1998 | 2023 |
Fundamental Metrics
Financial Performance| Metric | WYY | ANL |
|---|---|---|
| Price | $6.38 | $1.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 39.7K | 13.2K |
| Earning Date | 11-13-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,926,414.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $16.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $2.19 | $0.88 |
| 52 Week High | $7.55 | $2.99 |
Technical Indicators
Market Signals| Indicator | WYY | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 33.45 |
| Support Level | $6.25 | $1.32 |
| Resistance Level | $7.12 | $1.59 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 32.00 | 24.09 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.